Pyxis Oncology Inc (PYXS) - Total Assets
Based on the latest financial reports, Pyxis Oncology Inc (PYXS) holds total assets worth $105.60 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pyxis Oncology Inc - Total Assets Trend (2019–2024)
This chart illustrates how Pyxis Oncology Inc's total assets have evolved over time, based on quarterly financial data. Also see PYXS stock market capitalisation for the company's overall valuation and market capitalisation.
Pyxis Oncology Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Pyxis Oncology Inc's total assets of $105.60 Million consist of 84.3% current assets and 15.7% non-current assets. Review debt load of Pyxis Oncology Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.60 Million | 1.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Pyxis Oncology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Pyxis Oncology Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pyxis Oncology Inc's current assets represent 84.3% of total assets in 2024, a decrease from 99.5% in 2019.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2024, down from 99.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 1.7% of total assets.
Pyxis Oncology Inc Competitors by Total Assets
Key competitors of Pyxis Oncology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Genscript Biotech Corporation
F:G51
|
Germany | €4.85 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.78 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
Pyxis Oncology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.29 | 7.33 | 2.20 |
| Quick Ratio | 4.29 | 7.33 | 2.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $63.69 Million | $128.55 Million | $4.41 Million |
Pyxis Oncology Inc - Advanced Valuation Insights
This section examines the relationship between Pyxis Oncology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.26 |
| Latest Market Cap to Assets Ratio | 0.55 |
| Asset Growth Rate (YoY) | -9.5% |
| Total Assets | $157.18 Million |
| Market Capitalization | $86.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pyxis Oncology Inc's assets below their book value (0.55x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pyxis Oncology Inc's assets decreased by 9.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pyxis Oncology Inc (2019–2024)
The table below shows the annual total assets of Pyxis Oncology Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $157.18 Million | -9.52% |
| 2023-12-31 | $173.73 Million | -17.81% |
| 2022-12-31 | $211.38 Million | -24.51% |
| 2021-12-31 | $280.02 Million | +2658.56% |
| 2020-12-31 | $10.15 Million | -48.75% |
| 2019-12-31 | $19.81 Million | -- |
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candida… Read more